CHI Health Research Center is a keystone of CHI Health's vision to be a leader among America's best health systems. Through clinical research, physicians at CHI Health may offer their patients innovative, emerging treatments that are not currently available elsewhere. Participants in clinical trials play an active role in their own healthcare, gain access to new research treatments before they are widely available and help others by contributing to medical research.

What is a Clinical Trial?

A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people.

Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.

Clinical trials are ongoing and some may not be listed. If you have any questions please email the CHI Health Research office or call 402-343-8511.

Condition Description Disease Site
Cardiac SIELLO (Ref number:170)

This clinical study is a combined Pre-Market Study and Post-Approval Registry that will enroll up to 2124 subjects implanted with BIOTRONIK’s Siello pacing lead in the atrium and/or ventricle.

Cardiac REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) (Ref number:159)

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group STudy to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial)

Cardiac FOURIER (Ref number:174)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease

Cardiac Latitude TIMI 60 - Bergan (Ref number:178)

A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197)

Cardiac Latitdue TIMI 60 - Creighton (Ref number:179)

A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197)

Cardiac ODYSSEY (Ref number:168)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Cardiac GLORIA-AF  (Ref number:162)

Boehringer Ingelheim Pharmaceuticals, Inc., “GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation” (Phase II/III)

Gastroenterology Humira Legacy (Ref number:175)

Registry looking for patients with moderate to severe active ulcerative colitis who receive Humira with or without immunomodulatory therapy.

Nephrology ROXA (Ref number:176)

Randomized, double blind, placebo, controlled study evaluating the safety and efficacy of Roxadustat for treatment of Anemia in Chronic Kidney Disease patients not on dialysis.

Oncology Lilly Lung (Ref number:177)

Protocol I3Y-MC-JPBK(a) JUNIPER: A Randomized Phase 3 Study of Abemaciclib plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

Women's Health BV Harmony (Ref number:173)

A phase 3, double-blind, multicentre, randomised, placebo-controlled study to determine the efficacy and safety of SPL7013 Gel (VivaGel®) to prevent the recurrence of bacterial vaginosis